JPMorgan analyst Brian Cheng raised the firm’s price target on Monte Rosa Therapeutics (GLUE) to $31 from $30 and keeps an Overweight rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GLUE:
- Monte Rosa Therapeutics reports Q1 revenue $4.21M, consensus $11.39M
- Monte Rosa Therapeutics to present preclinical data on MRT-55811
- Monte Rosa Therapeutics price target lowered to $30 from $34 at Guggenheim
- Monte Rosa Therapeutics reports Q4 collaboration revenue $2.78M
- Monte Rosa Therapeutics reports Q4 revenue $2.8M, consensus $15.51